Department of Psychiatry and Psychotherapy
Vienna, 1090, Austria
NCT Number: NCT05320120
Subanesthetic ketamine is currently used as a rapid-acting antidepressant. It is an antagonist of the N-methyl-d-aspartate (NMDA) receptor, but former results indicate that its action also depends on the noradrenaline system and the locus coeruleus (LC).
Based on this known impact of ketamine on the sympathetic nervous system the aim of this study is to investigate the effects of intranasal esketamine on LC related attentional brain networks in task based functional MRI, to relate those attention network changes to behavioural measures and to predict ketamine related attention network changes by brain structure.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Vienna, 1090, Austria
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
56mg esketamine (2x Spravato® 28 mg nasal spray)
0.9% saline solution nasal spray
Time frame: up to two weeks
Blood oxygen level (BOLD) response assessed with functional magnetic resonance imaging (fMRI) during an arousal task
Rupert Lanzenberger
Other
Investigation of Intranasal Ketamine Related Changes in Attentional Brain Networks With Functional and Structural MRI: a Placebo Controlled, Randomized, Cross-over Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.